Ribociclib
Anaplastic Ganglioglioma
St. Jude Children's Research HospitalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Anaplastic Ganglioglioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trametinib National Cancer Institute (NCI) | Phase 4 | BB |
Dabrafenib National Cancer Institute (NCI) | Phase 4 | BB |
Carboplatin Novartis Pharmaceuticals | Phase 2 | B |
(+)-Vincristine Novartis Pharmaceuticals | Phase 2 | B |
Nivestim St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
Same molecule, other indications
Ribociclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →